Breast Cancer Update

Featuring an interview with Dr Erica Mayer, including the following topics:
Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)
Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)
Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)
Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)
Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)
Investigator Survey Results on Adjuvant Oral SERDs (43:02)
Discussion of Questions from the Community (45:00)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
Managing brain metastases in triple-negative breast cancer (6:30)
EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)
Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:
Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
CNS activity of TROP2-directed antibody-drug conjugates (5:36)
Autoimmune considerations with immunotherapy (10:09)
Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)
First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)
Adverse events (19:39)

CME information and select publications